Trial Profile
Randomized, Open-Label Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Bioavailability of a Single 100-mg Dose of BMS-986205 Commercial Tablet in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Linrodostat (Primary)
- Indications Cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 17 Jan 2018 Status changed from recruiting to completed.
- 19 Oct 2017 New trial record